Hemodynamic effects of levosimendan in acute myocardial infarction complicated by cardiogenic shock and high systemic vascular resistance

References

• Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999; 340: 1162–68
   PubMed Web of Science ®Google Scholar
• Babaev, A, Frederick, PD, Pasta, DJ, Every, N, Sichrovsky, T, Hochman, JS; NRMI Investigators. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005;294:448–54.
   PubMed Web of Science ®Google Scholar
• Hochman JS, Boland J, Sleeper LA, Porway M, Brinker J, Col J, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an international registry. SHOCK Registry Investigators. Circulation 1995; 91: 873–81
   PubMedGoogle Scholar
• Sonnenblick EH, Frishman WH, LeJemtel TH. Dobutamine: A new synthetic cardioactive sympathetic amine. N Engl J Med 1979; 300: 17–22
   PubMed Web of Science ®Google Scholar
• Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure: Mechanisms of action and recent clinical developments. 2. N Engl J Med 1986; 314: 349–58
   PubMed Web of Science ®Google Scholar
• Felker GM, O'Connor CM. Inotropic therapy for heart failure: An evidence-based approach. Am Heart J 2001; 142: 393–401
   PubMed Web of Science ®Google Scholar
• Haikala H, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol 1995; 27: 2155–65
   PubMed Web of Science ®Google Scholar
• Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000; 102: 2222–7
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1903–12
   PubMed Web of Science ®Google Scholar
• Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Steering Committee and Investigators of the levosimendan Infusion versus Dobutamine (LIDO) study: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet 2002; 360: 196–202
   PubMed Web of Science ®Google Scholar
• Moiseyev, VS, Poder, P, Andrejevs, N, Ruda, MY, Golikov, AP, Lazebnik, LB, , et al; RUSSLAN study investigators: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422–32.
   PubMed Web of Science ®Google Scholar
• Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004; 43: 2177–82
   PubMed Web of Science ®Google Scholar
• Tsagalou EP, Nanas JN. Resuscitation from adrenaline-resistant electro-mechanical dissociation facilitated by levosimendan in a young man with idiopathic dilated cardiomyopathy. Resuscitation 2006; 68: 147–49
   Google Scholar
• Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Lehtonen L, et al. Effects of a new calcium sensitizer, levosimendan, on hemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998; 19: 660–68
   PubMed Web of Science ®Google Scholar
• Ozdem SS, Yalcin O, Meiselman HJ, Baskurt OK, Usta C. The role of potassium channels in relaxant effect of levosimendan in rat small mesenteric arteries. Cardiovasc Drugs Ther 2006; 20: 123–27
   Google Scholar
• Usta C, Eksert B, Golbasi I, Bigat Z, Ozdem SS. The role of potassium channels in the vasodilatory effect of levosimendan in human internal thoracic arteries. Eur J Cardiothorac Surg 2006; 30: 329–32
   PubMed Web of Science ®Google Scholar
• Mebazaa, A, Nieminen, MS, Packer, M, Cohen-Solal, A, Kleber, FX, Pocock, SJ, . SURVIVE Investigators, et al.Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;2;1883–91.
   Google Scholar
• Lehmann A, Lang J, Boldt J, Isgro F, Kiessling AH. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit 2004; 10: T89–M93
   Google Scholar
• Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST elevation myocardial infarction: a series of cases. J Clin Pharmacol 2005; 45: 704–708
   Google Scholar
• Delle Karth G, Buberl A, Geppert A, Neunteufl T, Huelsmann M, Kopp C, et al. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 2003; 47: 1251–56
   PubMed Web of Science ®Google Scholar
• Alhashemi JA. Treatment of cardiogenic shock with levosimendan in combination with beta-adrenergic antagonists. Br J Anaesth 2005; 95: 648–50
   Google Scholar
• García-González MJ, Domínguez-Rodríguez A, Ferrer-Hita JJ, Abreu-Gonzalez P, Munoz MB. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail 2006; 8: 723–28
   PubMed Web of Science ®Google Scholar
• Karpman VL. The theoretical analysis of Fick's equation. On the centennial of the use of Fick's principle in physiology. Z Kardiol 1975; 64: 801–08
   PubMedGoogle Scholar
• Cotter G, Williams SG, Vered Z, Tan LB. Role of cardiac power in heart failure. Curr Opin Cardiol. 2003; 18: 215–22
   PubMed Web of Science ®Google Scholar
• Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003; 107: 2998–3002
   PubMed Web of Science ®Google Scholar
• Kohsaka, S, Menon, V, Lange, M, Dzavik, V, Sleeper, L, Hochman, J. High incidence of suspected sepsis complicating cardiogenic shock following acute myocardial infarction. Circulation. 2001;104((Suppl II)): II–483.
   Google Scholar
• Lim N, Dubois MJ, De Backer D, Vincent JL. Do all nonsurvivors of cardiogenic shock die with a low cardiac index?. Chest 2003; 124: 1885–91
   Google Scholar
• Nanas JN, Papazoglou P, Tsagalou EP, Ntalianis A, Tsolakis E, Terrovitis JV, et al. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol 2005; 95: 768–71
   PubMed Web of Science ®Google Scholar
• Nanas J, Papazoglou P, Terrovitis J, Kanakakis J, Dalianis A, Tsolakis E, et al. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol 2004; 94: 1329–32
   PubMed Web of Science ®Google Scholar
• Depre C, Vanoverschelde JL, Goudemant JF, Mottet I, Hue L. Protection against ischemic injury by nonvasoactive concentrations of nitric oxide synthase inhibitors in the perfused rabbit heart. Circulation 1995; 92: 1911–18
   Google Scholar
• Owlya R, Vollenweider L, Trueb L, Sartori C, Lepori M, Nicod P, et al. Cardiovascular and sympathetic effects of nitric oxide inhibition at rest and during static exercise in humans. Circulation 1997; 96: 3897–903
   PubMed Web of Science ®Google Scholar
• Cotter G, Kaluski E, Blatt A, Milovanov O, Moshkovitz Y, Zaidenstein R, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000; 101: 1358–61
   PubMed Web of Science ®Google Scholar
• Alexander JH, Reynolds HR, Stebbins AL, Dzavik V, Harrington RA, Van de Werf F, et al. TRIUMPH Investigators: Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007; 297: 1657–66
   PubMed Web of Science ®Google Scholar
• Garatti A, Russo C, Lanfranconi M, Colombo T, Bruschi G, Trunfio S, et al. Mechanical circulatory support for cardiogenic shock complicating acute myocardial infarction: an experimental and clinical review. ASAIO J 2007; 53: 278–87
   PubMedGoogle Scholar
• Russ MA, Prondzinsky R, Christoph A, Schlitt A, Buerke U, Söffker G, et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 2007; 35: 2732–9
   PubMed Web of Science ®Google Scholar